17:50 , Jul 20, 2018 |  BC Week In Review  |  Company News

PTC acquiring CNS gene therapy play Agilis

PTC Therapeutics Inc. (NASDAQ:PTCT) will acquire gene therapy company Agilis Biotherapeutics Inc. (Cambridge, Mass.), giving the rare disease company four products in development for CNS disorders. PTC will pay Agilis shareholders about $200 million up front,...
22:43 , Jul 19, 2018 |  BC Extra  |  Company News

PTC acquiring CNS gene therapy play Agilis

PTC Therapeutics Inc. (NASDAQ:PTCT) will acquire gene therapy company Agilis Biotherapeutics Inc. (Cambridge, Mass.), giving the rare disease company four products in development for CNS disorders. PTC will pay Agilis shareholders about $200 million up...
22:30 , Feb 2, 2018 |  BioCentury  |  Product Development

AA Viral meme

Gene therapy pioneer James Wilson’s revelation of two new types of toxicity in animals receiving high systemic doses of adeno-associated viral vectors is unlikely to herald a major disruption of the AAV space, though it...
23:44 , May 10, 2017 |  BC Extra  |  Company News

Management tracks

RNA company Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) announced several additions. The biotech named Alan Eisenberg VP of global public policy and government relations; Theresa Heggie SVP and head of Europe and Canada; Peter Smith SVP of...
23:33 , Apr 25, 2017 |  BC Extra  |  Company News

Management tracks

Eye disease company Ophthotech Corp. (NASDAQ:OPHT) said co-founder and CEO David Guyer will become executive chairman, effective July 1. President and CFO Glenn Sblendorio will become CEO and remain president. Ophthotech promoted SVP of Finance...
00:39 , Nov 22, 2016 |  BC Week In Review  |  Clinical News

AGIL-AADC regulatory update

FDA granted rare pediatric disease designation to Agilis’ AGIL-AADC to treat Aromatic L-Amino Acid Decarboxylase (AADC) deficiency. The product is an adeno-associated viral (AAV) vector encoding the dopa decarboxylase (DDC; AADC) gene. Agilis Biotherapeutics LLC, Cambridge,...
07:00 , Sep 13, 2016 |  BC Extra  |  Company News

Management tracks

Gene therapy company NightstaRx Ltd. (London, U.K.) named Gregory Robinson CSO. He was CSO at Agilis Biotherapeutics LLC (Cambridge, Mass.). Wound care company Acelity L.P. Inc. (San Antonio, Texas) said EVP and CFO Tom Casey...
07:00 , Oct 12, 2015 |  BC Week In Review  |  Company News

University of South Florida, Agilis Biotherapeutics deal

The university granted Agilis exclusive, worldwide rights to develop and commercialize Reelin (RELN) replacement technologies to treat cognitive disorders. Agilis will provide research funding to the university. The university deferred questions Agilis, which declined...
07:00 , Jun 15, 2015 |  BC Week In Review  |  Company News

University of South Florida, Agilis Biotherapeutics deal

The university granted Agilis exclusive, worldwide rights to develop and commercialize UBE3a gene therapies to treat Angelman syndrome. The university will receive an undisclosed upfront payment, plus undisclosed milestones and royalties. University of South Florida,...
08:00 , Dec 8, 2014 |  BC Week In Review  |  Company News

Agilis Biotherapeutics management update

Agilis Biotherapeutics LLC, Germantown, Md.   Business: Neurology, Gene/Cell therapy   Hired: Greg Robinson as CSO, formerly senior director of rare diseases business development at Shire plc   ...